DJO Global said this week that it hired Jeffery McCaully as global president of its surgical business, effectively immediately.
McCaulley succeeded Brady Shirley, who was named DJO’s president & CEO in November last year.
McCaulley previously served as president & CEO of Smiths Medical, as well as president of Zimmer Biomet‘s (NYSE:ZBH) global reconstructive unit, where he led 5 global business units. McCaulley has also worked as VP and GM of the Medtronic‘s (NYSE:MDT) global diabetes unit.
“Our surgical business’ best in market performance has and will continue to be the key transformation catalyst in our company. I am excited to combine Jeff’s talent and experience in the space with our exceptional leadership team,” Shirley said in prepared remarks. “Throughout his career, Jeff has a proven track record of accelerating innovation, improving employee and customer engagement, and delivering results. I look forward to this great next chapter for DJO Surgical!”
“I am very excited to be joining Brady and the team at DJO,” McCaulley added. “The growth in recent years has been spectacular and I am convinced that we are positioned to continue to make significant market share gains across our portfolio and have the right internal and external teams to improve key areas of patient care and experience.”
Insulet appoints new CCO
Insulet (NSDQ:PODD) said this week that it named Bret Christensen as chief commercial officer to lead the company’s sales, marketing, customer care, market access and advocacy.
Christensen formerly worked at Myriad Genetics, serving as GM of the company’s preventive care business.
“I am thrilled to welcome a leader of Bret’s caliber to run Insulet’s commercial operations,” president & chief operating officer Shacey Petrovic said. “Over the past year, Insulet has achieved considerable growth and we remain focused on further penetrating both the diabetes and drug delivery markets. Bret’s extensive commercial expertise will be a tremendous asset as we drive execution of our strategic plan.”
“Insulet has a differentiated platform, a significant growth opportunity and a terrific team,” Christensen added. “I am excited to join at a time when the company is rapidly expanding and making such great strides in product innovation.”
In connection with her departure, Trecker is eligible to receive one year’s base salary of $315,000 and a lump sum payment equal to the amount that Integer would have contributed toward her health, vision and dental insurance coverage for a 1 year period. The company has not made clear who will replace Trecker.
In his role as commercial director, Barlow will support the pre-commercialization activities and launch of EnXray’s low energy x-ray resterilization equipment.
“Robert’s understanding of the global medical device industry and success building and leading teams capable of introducing new technology will be of great benefit to EnXray,” co-founder & CEO Ed Cappabianca said.
“I am delighted to be joining EnXray at a time when markets are being disrupted by new and innovative services and solutions. Our LEXR System is one of those pioneering technologies that will challenge the status quo and create significant competitive advantages for our customers. We have an incredibly exciting journey ahead of us,” Barlow added.
“I am excited to welcome Skip as a member of the NuVasive executive leadership team,” chairman & CEO Gregory Lucier said. “Skip has led complex, global commercial enterprises in Europe, the Middle East, Africa, Japan, Asia Pacific and the United States within the healthcare and spine technology industries. He brings significant strategic and operational expertise in market entry and development and proficiency in maintaining P&L responsibility, both of which are key elements as we scale and expand our high-growth international channels. We are pleased to have a global leader of Skip’s caliber join NuVasive’s world-class leadership team at this time as we accelerate past $1 billion in revenue, enhance our international operations and continue to change patients’ lives around the world.”
- CytoSorbents names chief medical exec
- Daxor appoints CFO
- Companion Medical adds 2 to leadership team
- Gecko Biomedical builds out team
- HeartFlow names CCO
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.